1. Home
  2. TNXP vs ORMP Comparison

TNXP vs ORMP Comparison

Compare TNXP & ORMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tonix Pharmaceuticals Holding Corp.

TNXP

Tonix Pharmaceuticals Holding Corp.

HOLD

Current Price

$12.32

Market Cap

192.9M

Sector

Health Care

ML Signal

HOLD

Logo Oramed Pharmaceuticals Inc.

ORMP

Oramed Pharmaceuticals Inc.

HOLD

Current Price

$4.61

Market Cap

165.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TNXP
ORMP
Founded
2007
2002
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
192.9M
165.3M
IPO Year
2008
2010

Fundamental Metrics

Financial Performance
Metric
TNXP
ORMP
Price
$12.32
$4.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
567.5K
470.5K
Earning Date
05-11-2026
05-14-2026
Dividend Yield
N/A
6.51%
EPS Growth
91.75
412.50
EPS
N/A
0.91
Revenue
$13,107,000.00
$2,000,000.00
Revenue This Year
$558.11
N/A
Revenue Next Year
$38.29
N/A
P/E Ratio
N/A
$5.05
Revenue Growth
29.85
49.25
52 Week Low
$10.03
$1.98
52 Week High
$69.65
$5.19

Technical Indicators

Market Signals
Indicator
TNXP
ORMP
Relative Strength Index (RSI) 49.93 60.43
Support Level $12.08 $3.69
Resistance Level $13.17 $5.10
Average True Range (ATR) 0.87 0.32
MACD 0.15 0.08
Stochastic Oscillator 61.08 58.74

Price Performance

Historical Comparison
TNXP
ORMP

About TNXP Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.

About ORMP Oramed Pharmaceuticals Inc.

Oramed Pharmaceuticals Inc is a pharmaceutical company that is engaged in the research and development of pharmaceutical solutions with a technology platform that allows for the oral delivery of therapeutic proteins. The company has developed an oral dosage form intended to withstand the harsh environment of the gastrointestinal tract and effectively deliver active insulin or other proteins. Its product pipeline includes ORMD-0801 for Diabetes, ORMD-0801 for NASH, and ORMD 0901.

Share on Social Networks: